Abstract
Protein kinases are key factors in signal transduction, playing a pivotal role in the initiation, propagation and regulation of immunologic responses. In contrast to protein- protein interaction they are considered to be “drugable” by small molecular weight inhibitors. Thus kinases moved into in the focus as promising drug targets for the therapy of inflammatory and autoimmune diseases. Whereas some kinase inhibitors are in clinical development already, most others are in early stages of research or still require validation. Recently, major progress has been made in elucidating the complete human kinome, in understanding molecular mechanisms of protein kinase action in inflammation as well as in regard to technologies suitable for in vitro and in vivo target validation, inhibitor screening and its structural refinement. Starting with some general points, this review summarise some recent findings and developments and prepare the stage for the subsequent review articles published in this hot topic issue. It is the purpose to highlight both the opportunities and the issues associated with kinases as drug targets and to enable the reader to keep up with this fast developing field, that is of substantial interest for basic and applied scientists.
Keywords: Drug targets, Inflammation, Immune regulation, Inhibitors, Kinases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview
Volume: 6 Issue: 1
Author(s): Khusru Asadullah and Matthias Gaestel
Affiliation:
Keywords: Drug targets, Inflammation, Immune regulation, Inhibitors, Kinases
Abstract: Protein kinases are key factors in signal transduction, playing a pivotal role in the initiation, propagation and regulation of immunologic responses. In contrast to protein- protein interaction they are considered to be “drugable” by small molecular weight inhibitors. Thus kinases moved into in the focus as promising drug targets for the therapy of inflammatory and autoimmune diseases. Whereas some kinase inhibitors are in clinical development already, most others are in early stages of research or still require validation. Recently, major progress has been made in elucidating the complete human kinome, in understanding molecular mechanisms of protein kinase action in inflammation as well as in regard to technologies suitable for in vitro and in vivo target validation, inhibitor screening and its structural refinement. Starting with some general points, this review summarise some recent findings and developments and prepare the stage for the subsequent review articles published in this hot topic issue. It is the purpose to highlight both the opportunities and the issues associated with kinases as drug targets and to enable the reader to keep up with this fast developing field, that is of substantial interest for basic and applied scientists.
Export Options
About this article
Cite this article as:
Asadullah Khusru and Gaestel Matthias, Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (1) . https://dx.doi.org/10.2174/187152307779939769
DOI https://dx.doi.org/10.2174/187152307779939769 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy
Inflammation & Allergy - Drug Targets (Discontinued) Naturally Arising CD25+CD4+ Regulatory T Cells in Maintaining Immunologic Self-Tolerance and Preventing Autoimmune Disease
Current Molecular Medicine TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities
Endocrine, Metabolic & Immune Disorders - Drug Targets Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Vaccination Against High Blood Pressure
Current Pharmaceutical Design Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Development and Chemistry of Histamine H4 Receptor Ligands as Potential Modulators of Inflammatory and Allergic Responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Current Pharmaceutical Design Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry Insights into the Pathogenesis of Type 1 Diabetes A Hint for Novel Immunospecific Therapies
Current Molecular Medicine Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets